Product Description
for treating dysmenorrhea with endometriosis (Sourced from: https://www.nobelpharma.co.jp/en/news/20030101-p822/)
Mechanisms of Action: ER Agonist, PR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nobelpharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Endometriosis|Other
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00746096 |
IKH-01-6 | P3 |
Completed |
Other |
2009-09-01 |
2019-03-18 |
Treatments |
|
JapicCTI-050113 |
JapicCTI-050113 | P3 |
Completed |
Endometriosis |
None |
Recent News Events
Date |
Type |
Title |
|---|